Combined atorvastatin and coenzyme Q10 improve the left ventricular function in isoproterenol-induced heart failure in rat
The effect of atorvastatin on cardiac remodeling, function, and homodynamic parameters in isoproterenol-induced heart failure was evaluated in the present study. A subcutaneous injection of isoproterenol (5 mg/kg/day) for 10 days was used for the induction of heart failure. Isoproterenol administrat...
Saved in:
Published in | European journal of pharmacology Vol. 666; no. 1; pp. 135 - 141 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Amsterdam
Elsevier B.V
01.09.2011
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The effect of atorvastatin on cardiac remodeling, function, and homodynamic parameters in isoproterenol-induced heart failure was evaluated in the present study. A subcutaneous injection of isoproterenol (5
mg/kg/day) for 10
days was used for the induction of heart failure. Isoproterenol administration produced intensive myocardial necrosis and fibrosis with a significant decrease in the arterial pressure indices, heart rate, contractility (LVdP/dt
max) and relaxation (LVdP/dt
min), but an increase in the left ventricular end-diastolic pressure. Rats were randomly assigned to control, treatment with only atorvastatin, and treatment with atorvastatin plus coenzyme Q10. Histopathological analysis showed a marked attenuation of myocyte necrosis and interstitial fibrosis in all atorvastatin treated groups (P
<
0.001). A low dose of atorvastatin (5
mg/kg/day) significantly improved the left ventricular systolic pressure, contractility and relaxation (P
<
0.01). On the contrary, a high dose of atorvastatin (20
mg/kg/day) worsened the isoproterenol-induced left ventricular dysfunction by a further reduction of LV
dP/
dt
max from +
2780
±
94 to +
1588
±
248 (mm
Hg/s; P
<
0.01) and LV
dP/
dt
min from −
2007
±
190 to −
2939
±
291 (mm
Hg/s; P
<
0.05). Co-administration of coenzyme Q10 with atorvastatin reversed the hemodynamic depression and the left ventricular dysfunction to a high level (P
<
0.001). There was a lower level of LVEDPs in the atorvastatin
+
coenzyme Q10 treated groups (3
±
1 and 4
±
1.4 versus 8
±
3.5 and 14
±
3.6
mm
Hg, respectively), thereby suggesting improvement in the myocardial stiffness by the combined coenzyme Q10 and atorvastatin treatment. The atorvastatin therapy attenuated myocardial necrosis and fibrosis in isoproterenol-induced heart failure. However, a high dose of the drug considerably worsened the left ventricular dysfunction and hemodynamic depression, which was reversed by coenzyme Q10 co-administration. |
---|---|
ISSN: | 0014-2999 1879-0712 |
DOI: | 10.1016/j.ejphar.2011.04.061 |